Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Pètra M. Braam"'
Autor:
Tom Rozema, Francine E.M. Voncken, Stefan A W Bouwense, L. Valkenburg-van Iersel, Vivianne C. G. Tjan-Heijnen, Paul M. Jeene, G.J. Blom, J.A. Bogers, Nicolien Kasperts, Pètra M. Braam, M.A. de Jong, Frank J. P. Hoebers, S. M. E. Geurts, Christina T. Muijs, J. de Vos-Geelen, G.A.P. Nieuwenhuijzen
Publikováno v:
EJSO, 47(8), 2016-2022. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47, 8, pp. 2016-2022
European Journal of Surgical Oncology, 47, 2016-2022
European Journal of Surgical Oncology, 47(8), 2016-2022. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47, 8, pp. 2016-2022
European Journal of Surgical Oncology, 47, 2016-2022
European Journal of Surgical Oncology, 47(8), 2016-2022. ELSEVIER SCI LTD
Introduction: The aim of this retrospective study was to determine the patterns of recurrence and overall survival (OS) in patients achieving clinical complete response after treatment with definitive chemoradiation (CRT) for proximal esophageal canc
Autor:
Karin Muller, Vera Oppedijk, Sherif Y. El Sharouni, Daphne van Kampen, Marjolein Y.V. Homs, Peter D. Siersema, Maarten C.C.M. Hulshof, Bram D. Vermeulen, Maaike Berbee, Paul M. Jeene, Tom Rozema, Pètra M. Braam, Peter S.N. van Rossum, I.M. Lips
Publikováno v:
Radiotherapy and Oncology, 155, 73-79
Radiotherapy and oncology, 155, 73-79. Elsevier Ireland Ltd
Radiotherapy and Oncology, 155, 73-79. Elsevier Ireland Ltd
Radiotherapy and Oncology, 155, pp. 73-79
Radiotherapy and Oncology, 155, 73-79. ELSEVIER IRELAND LTD
Radiotherapy and oncology, 155, 73-79. Elsevier Ireland Ltd
Radiotherapy and Oncology, 155, 73-79. Elsevier Ireland Ltd
Radiotherapy and Oncology, 155, pp. 73-79
Radiotherapy and Oncology, 155, 73-79. ELSEVIER IRELAND LTD
Contains fulltext : 229287.pdf (Publisher’s version ) (Open Access) BACKGROUND AND PURPOSE: A matched comparison of external beam radiotherapy (EBRT) versus brachytherapy recently demonstrated that EBRT appears at least as effective for palliating
Autor:
Olga Husson, Jos A. van der Hage, Jacco J de Haan, Vicky L. M. N. Soomers, Dirk J. Grünhagen, Cas Drabbe, Winan J. van Houdt, Winette T. A. van der Graaf, Pètra M. Braam, Kristien Keymeulen
Publikováno v:
Cancers, 13(4):679, 1-16. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Cancers, 13(4), 679. MDPI} {AG
Cancers, 13(4):679. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 4
Cancers, 13(4):679. MDPI AG
Cancers, 13(4). MDPI
Cancers, Vol 13, Iss 679, p 679 (2021)
Cancers, 13, 4
Cancers, 13
Cancers, 13(4), 679. MDPI} {AG
Cancers, 13(4):679. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 4
Cancers, 13(4):679. MDPI AG
Cancers, 13(4). MDPI
Cancers, Vol 13, Iss 679, p 679 (2021)
Cancers, 13, 4
The aim of this study was to explore the experience of rare cancer patients with the healthcare system and examine differences between age groups (adolescents and young adults (AYA, 18–39 years), older adults (OA, 40–69 years) and elderly (≥70
Autor:
Onne Reerink, Merel S. Koedijk, W. Schillemans, C.J.A. Haasbeek, Heleen M. Ceha, B.J.M. Heijmen, Jeroen Buijsen, Karin Muller, Martijn P.M. Intven, Alejandra Méndez Romero, F. Koppe, Ellen M. Hendriksen, Rob M. van Os, Ines Joye, Pètra M. Braam, Edwin P.M. Jansen, Henrike Westerveld
Publikováno v:
International Journal of Radiation Oncology, Biology, Physics, 109, 5, pp. 1377-1386
International Journal of Radiation Oncology, Biology, Physics, 109, 1377-1386
Méndez Romero, A, Schillemans, W, van Os, R, Koppe, F, Haasbeek, C J, Hendriksen, E M, Muller, K, Ceha, H M, Braam, P T M, Reerink, O, Intven, M P M, Joye, I, Jansen, E P M, Westerveld, H, Koedijk, M S, Heijmen, B J M & Buijsen, J 2021, ' The Dutch–Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases ', International Journal of Radiation Oncology Biology Physics, vol. 109, no. 5, pp. 1377-1386 . https://doi.org/10.1016/j.ijrobp.2020.11.045
International Journal of Radiation Oncology Biology Physics, 109(5), 1377-1386. Elsevier Inc.
International Journal of Radiation Oncology, Biology, Physics, 109, 1377-1386
Méndez Romero, A, Schillemans, W, van Os, R, Koppe, F, Haasbeek, C J, Hendriksen, E M, Muller, K, Ceha, H M, Braam, P T M, Reerink, O, Intven, M P M, Joye, I, Jansen, E P M, Westerveld, H, Koedijk, M S, Heijmen, B J M & Buijsen, J 2021, ' The Dutch–Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases ', International Journal of Radiation Oncology Biology Physics, vol. 109, no. 5, pp. 1377-1386 . https://doi.org/10.1016/j.ijrobp.2020.11.045
International Journal of Radiation Oncology Biology Physics, 109(5), 1377-1386. Elsevier Inc.
Contains fulltext : 232797.pdf (Publisher’s version ) (Open Access) PURPOSE: Although various studies have reported that stereotactic body radiation therapy (SBRT) for liver metastases has high local control rates and relatively low toxicity, most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075ce2c8c7f8506266a7d55249281430
Autor:
A.N. Scholten, Winan J. van Houdt, Rick L. Haas, Pètra M. Braam, Kirsten van Langevelde, Jules Lansu, Yvonne Schrage, Erik van Werkhoven
Publikováno v:
European Journal of Surgical Oncology, 47, 10, pp. 2633-2639
European Journal of Surgical Oncology, 47, 2633-2639
EJSO-European Journal of Surgical Oncology, 47(10), 2633-2639. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47, 2633-2639
EJSO-European Journal of Surgical Oncology, 47(10), 2633-2639. ELSEVIER SCI LTD
Background: Histotype specific neoadjuvant therapy response data is scarce in soft tissue sarcomas. This study aimed to assess the impact of a moderate radiotherapy (RT) dose on resectability and to correlate MRI parameters to pathological treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7838e8e3c1444f736d1a65cac5526f45
https://repository.ubn.ru.nl/handle/2066/238185
https://repository.ubn.ru.nl/handle/2066/238185
Autor:
A.N. Scholten, Augustinus D.G. Krol, Aisha Miah, Nina L. Jebsen, Elizabeth H. Baldini, Uta Flucke, Khin Thway, Houke M. Klomp, Piet van den Ende, Winan J. van Houdt, Hester van Boven, Erik van Werkhoven, Yvonne Schrage, Judith V.M.G. Bovée, Jos A. van der Hage, Jan F. Ubbels, Rick L. Haas, Pètra M. Braam, Johannes J. Bonenkamp, Shane Zaidi, Øyvind S. Bruland, Jules Lansu, Winette T. A. van der Graaf, Frits van Coevorden
Publikováno v:
JAMA Oncology, 7(1):205865. American Medical Association
JAMA Oncology, 7(1). American Medical Association
JAMA Oncology, 7(1). AMER MEDICAL ASSOC
Jama Oncology, 7
JAMA Oncol
JAMA oncology, 7(1), 1-8. AMER MEDICAL ASSOC
Jama Oncology, 7, 1
JAMA Oncology, 7(1). American Medical Association
JAMA Oncology, 7(1). AMER MEDICAL ASSOC
Jama Oncology, 7
JAMA Oncol
JAMA oncology, 7(1), 1-8. AMER MEDICAL ASSOC
Jama Oncology, 7, 1
Item does not contain fulltext IMPORTANCE: Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosens
Autor:
H.J.T. Rutten, Pètra M. Braam, Johannes A. Bogers, Paul M. Jeene, Peter D. Siersema, Bram D. Vermeulen, Robin Krol, Jasmijn Sijben
Publikováno v:
Practical radiation oncology, 10(4), e255-e263. Elsevier BV
Practical Radiation Oncology, 10, E255-E263
Practical Radiation Oncology, 10, 4, pp. E255-E263
Practical Radiation Oncology, 10, E255-E263
Practical Radiation Oncology, 10, 4, pp. E255-E263
Purpose Clinical evidence regarding optimal radiation dose for palliation of dysphagia from esophageal cancer is generally lacking. In an effort to investigate optimal radiation dose, we assessed 2 different radiation schedules for palliation of dysp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2400d92b847f1f30c67242bed178de8
https://pure.amc.nl/en/publications/lowdose-versus-highdose-radiation-therapy-for-the-palliation-of-dysphagia-from-esophageal-cancer-a-multicenter-retrospective-cohort-study(d67dde00-52d2-41ac-97d2-4da156996028).html
https://pure.amc.nl/en/publications/lowdose-versus-highdose-radiation-therapy-for-the-palliation-of-dysphagia-from-esophageal-cancer-a-multicenter-retrospective-cohort-study(d67dde00-52d2-41ac-97d2-4da156996028).html
Autor:
Lukas J.A. Stalpers, Charles G.H.J. Niël, Hanneke Vos-Westerman, Johanna G. H. van Nes, Joost J. Nuyttens, Peter Koper, Tom Rozema, Jaap D. Zindler, Kim C. de Vries, Paul M. Jeene, Joost J.C. Verhoeff, Ilona Schmeets, Johannes J.M. Kwakman, Pètra M. Braam, Yvette M. van der Linden, Stefan Hutschemaekers, G. Wester
Publikováno v:
Acta Oncologica, 57, 637-643
Acta Oncologica, 57, 5, pp. 637-643
Acta Oncologica, 57(5), 637-643. Informa Healthcare
Acta Oncologica, 57, 637. Informa Healthcare
Acta Oncologica, 57(5), 637-643
Jeene, P M, de Vries, K C, van Nes, J G H, Kwakman, J J M, Wester, G, Rozema, T, Braam, P M, Zindler, J D, Koper, P, Nuyttens, J J, Vos-Westerman, H A, Schmeets, I, Niël, C G H J, Hutschemaekers, S, van der Linden, Y M, Verhoeff, J J C & Stalpers, L J A 2018, ' Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014 ', Acta Oncologica, vol. 57, no. 5, pp. 637-643 . https://doi.org/10.1080/0284186X.2017.1418534
Acta oncologica (Stockholm, Sweden), 57(5), 637-643. Informa Healthcare
Acta Oncologica, 57(5), 637-643. Routledge/Taylor & Francis Group
Acta Oncologica, 57, 5, pp. 637-643
Acta Oncologica, 57(5), 637-643. Informa Healthcare
Acta Oncologica, 57, 637. Informa Healthcare
Acta Oncologica, 57(5), 637-643
Jeene, P M, de Vries, K C, van Nes, J G H, Kwakman, J J M, Wester, G, Rozema, T, Braam, P M, Zindler, J D, Koper, P, Nuyttens, J J, Vos-Westerman, H A, Schmeets, I, Niël, C G H J, Hutschemaekers, S, van der Linden, Y M, Verhoeff, J J C & Stalpers, L J A 2018, ' Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014 ', Acta Oncologica, vol. 57, no. 5, pp. 637-643 . https://doi.org/10.1080/0284186X.2017.1418534
Acta oncologica (Stockholm, Sweden), 57(5), 637-643. Informa Healthcare
Acta Oncologica, 57(5), 637-643. Routledge/Taylor & Francis Group
Background: Whole brain radiotherapy (WBRT) is considered standard of care for patients with multiple brain metastases or unfit for radical treatment modalities. Recent studies raised discussion about the expected survival after WBRT. Therefore, we a
Autor:
Michel Öllers, Niek van Wieringen, Xavier Mirabel, Ben J.M. Heijmen, François E. J. A. Willemssen, Karin Haustermans, Alejandra Méndez Romero, M. Wendling, L. Depuydt, Onne Reerink, Roy S. Dwarkasing, Oliver Riesterer, Wilko F.A.R. Verbakel, Enrica Seravalli, Cornelis J.A. Haasbeek, Steven J. M. Habraken, Abdul Wahab M. Sharfo, Thomas Lacornerie, Pètra M. Braam, Henrike Westerveld, Tom Depuydt, Jeroen Buijsen, Stephanie Tanadini-Lang, R. Weytjens
Publikováno v:
Radiotherapy and oncology, 125(3), 507-513. Elsevier Ireland Ltd
Radiotherapy and oncology
Radiotherapy and Oncology, 125, 507-513
Habraken, S J M, Sharfo, A W M, Buijsen, J, Verbakel, W F A R, Haasbeek, C J A, Öllers, M C, Westerveld, H, van Wieringen, N, Reerink, O, Seravalli, E, Braam, P M, Wendling, M, Lacornerie, T, Mirabel, X, Weytjens, R, Depuydt, L, Tanadini-Lang, S, Riesterer, O, Haustermans, K, Depuydt, T, Dwarkasing, R S, Willemssen, F E J A, Heijmen, B J M & Méndez Romero, A 2017, ' The TRENDY multi-center randomized trial on hepatocellular carcinoma – Trial QA including automated treatment planning and benchmark-case results ', Radiotherapy and Oncology, vol. 125, no. 3, pp. 507-513 . https://doi.org/10.1016/j.radonc.2017.09.007
Radiotherapy and Oncology, 125(3), 507-513. Elsevier Ireland Ltd
Radiotherapy and Oncology, 125, 3, pp. 507-513
Radiotherapy and oncology
Radiotherapy and Oncology, 125, 507-513
Habraken, S J M, Sharfo, A W M, Buijsen, J, Verbakel, W F A R, Haasbeek, C J A, Öllers, M C, Westerveld, H, van Wieringen, N, Reerink, O, Seravalli, E, Braam, P M, Wendling, M, Lacornerie, T, Mirabel, X, Weytjens, R, Depuydt, L, Tanadini-Lang, S, Riesterer, O, Haustermans, K, Depuydt, T, Dwarkasing, R S, Willemssen, F E J A, Heijmen, B J M & Méndez Romero, A 2017, ' The TRENDY multi-center randomized trial on hepatocellular carcinoma – Trial QA including automated treatment planning and benchmark-case results ', Radiotherapy and Oncology, vol. 125, no. 3, pp. 507-513 . https://doi.org/10.1016/j.radonc.2017.09.007
Radiotherapy and Oncology, 125(3), 507-513. Elsevier Ireland Ltd
Radiotherapy and Oncology, 125, 3, pp. 507-513
Background and purpose: The TRENDY trial is an international multi-center phase-II study, randomizing hepatocellular carcinoma (HCC) patients between transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT) with a target
Autor:
Andrzej Piwowar, Fransje Aa Valster, Jeffrey P.B.M. Braak, Marije Ie Appels, Frits van Coevorden, Niels H Nielsen, Johanna E.A. Portielje, Jeroen Buijsen, Petra Flygare, Marije Slingerland, Nicole C.T. van Grieken, Jetske M. Meerum Terwogt, Maartje Los, Mattias Elmlund, Henk Boot, Rob L. H. Jansen, Johanna W. van Sandick, A. Haringhuizen, Johannes J. Bonenkamp, Harm van Tinteren, Edwin P.M. Jansen, Henk H. Hartgrink, Jaap De Boer, Anouk K. Trip, Ge Jpm Jonkers, Marie Louise Jespersen, Cecillia Lagerbäck, Per Edlund, Marco B Polée, Mats Perman, J (Hans)-Martin Mb Otten, Marjan A Van Dijk, Danny Houtsma, A (Bert) Jan Ten Tije, Arnold Baars, Olaf Jl Loosveld, Maud M. Geenen, Maarten C.C.M. Hulshof, Gerrit-Jan Veldhuis, Erik W Muller, Geert-Jan Creemers, Annelie Je Vulink, Quirijn A. J. Eijsbouts, Annerie Slot, Diane Grootenboers, Hein Putter, Ellen M Hendriksen, Maurice J.C. van der Sangen, Fabiënne A. R. M. Warmerdam, Tom Rozema, HA A. Maurits Swellengrebel, Henk K Van Halteren, Ate van der Gaast, Marcel Verheij, Richard Van Hilligersberg, Helene Hörberg, Pehr Lind, Annemieke Cats, Cornelis J.H. van de Velde, Jitty M Smit, Alex L. T. Imholz, Donald L. van der Peet, Aart Van Bochove, Henk M.W. Verheul, Adelheid Me Van der Torren-Conze, Frans L. G. Erdkamp, Dick Johan van Spronsen, Mark I. van Berge Henegouwen, Ernst Jan Spillenaar Bilgen, Johanna Mgh Van Riel, Marien O Den Boer, Hanneke W. M. van Laarhoven, Marjolein Em Rentinck, Ron C Rietbroek, Bengt Johansson, David Borg, Anders Johnsson, Aart Beeker, Reinoud J. B. Blaisse, Miriam Koopman, Daan Ten Bokkel Huinink, Karen J. Neelis, Elma Meershoek-Klein Kranenbarg, Djamila Boerma, Heleen M. Ceha, Bea C Tanis, Marie-Cecile Jc Legdeur, O Aart Van Dobbenburgh, Steven Vanhoutvin, Sjoerd Hovenga, Karolina Sikorska, Pètra M Braam, H Pieter van den Berg, Huub van der Mijle, Marianne Nordsmark, Bengt Glimelius
Publikováno v:
lancet oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21019f3b155741c37a17771cdb957cb
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html